A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in the treatment of patients with bipolar I disorder with a major depressive episode. CN138-146 LT is the 26-Week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in the treatment of patients with bipolar I disorder with a major depressive episode. CN138-146 LT is the 26-Week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Bipolar I disorders; Depression
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 01 Feb 2008 Results published (1101923)
    • 30 Jan 2007 Status changed from recruiting
    • 06 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top